Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KAT7 | O95251 | 1/20 | 0.34 |
| ▸ | KAT6B | Q8WYB5 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.34 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007593 | 1.00 | F2 (0.39) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL5007590 | 0.90 | F2 (0.40) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL5009630 | 0.83 | CYP1A2 (0.36) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL5009632 | 0.83 | CYP1A2 (0.36) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL13994264 | 0.81 | SLC22A12 (0.34) | F2PRSS1PRSS2PRSS3KMT2A | |
| SCHEMBL2428796 | 0.81 | CYP1A2 (0.40) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL14529091 | 0.79 | F2 (0.43) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL13994242 | 0.77 | CYP3A4 (0.38) | F2PRSS1PRSS2PRSS3CYP1A2 | |
| SCHEMBL13994230 | 0.76 | LMNA (0.38) | CYP1A2CYP2C19KMT2ALMNACYP3A4 | |
| SCHEMBL5012802 | 0.76 | LMNA (0.38) | CYP1A2CYP2C19KMT2ALMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210280887-A1 | SYSTEM AND METHOD FOR ELECTROCHEMICAL ENERGY CONVERSION AND STORAGE | COLORADO SCHOOL OF MINES | 2021-09-09 | — | — | US | disclosed |
| US-20180053957-A1 | SYSTEM AND METHOD FOR ELECTROCHEMICAL ENERGY CONVERSION AND STORAGE | COLORADO SCHOOL OF MINES | 2018-02-22 | — | — | US | disclosed |
| CN-105246962-A | Metal nanowire-containing composition | SEIKO PMC CORP | 2016-01-13 | — | — | CN | disclosed |
| CN-101463193-A | Dye composition for lens | PRODISC TECHNOLOGY INC (CN) | 2009-06-24 | — | — | CN | disclosed |
| US-20080300280-A1 | Cyanobenzene Compounds for Combating Animal Pests | BASF SE (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080241092-A1 | Administering a potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic | RELYPSA, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080241093-A1 | A potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic | RELYPSA, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080233073-A1 | Administering potassium binding polymer of alpha-fluoroacrylic acid comprising counterion of calcium crosslinked with divinylbenzene, (m)ethylenebisacrylamide, N,N'-bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, polyvinyl ether, polyallylether; hyperkalemia | RELYPSA, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233073-A1 | Administering potassium binding polymer of alpha-fluoroacrylic acid comprising counterion of calcium crosslinked with divinylbenzene, (m)ethylenebisacrylamide, N,N'-bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, polyvinyl ether, polyallylether; hyperkalemia | KCNH3, KCNAB1, KCNMB1 | F2 282/4885PRSS1 565/4885PRSS2 1109/4885 |
| US-20080241092-A1 | Administering a potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic | KCNN3, ATP6V1B1, KCNK3 | F2 681/4885PRSS1 4709/4885PRSS2 4432/4885 |
| US-20080300280-A1 | Cyanobenzene Compounds for Combating Animal Pests | NR0B1, NR0B2, CBR1 | F2 2529/4885PRSS1 3726/4885PRSS2 2884/4885 |
| US-20080241093-A1 | A potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic | KCNN3, KCNK3, KCNK9 | F2 601/4885PRSS1 4720/4885PRSS2 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.